1. Home
  2. TSLX vs BLTE Comparison

TSLX vs BLTE Comparison

Compare TSLX & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSLX
  • BLTE
  • Stock Information
  • Founded
  • TSLX 2010
  • BLTE 2018
  • Country
  • TSLX United States
  • BLTE United States
  • Employees
  • TSLX N/A
  • BLTE N/A
  • Industry
  • TSLX Investment Managers
  • BLTE Biotechnology: Pharmaceutical Preparations
  • Sector
  • TSLX Finance
  • BLTE Health Care
  • Exchange
  • TSLX Nasdaq
  • BLTE Nasdaq
  • Market Cap
  • TSLX 2.2B
  • BLTE 1.7B
  • IPO Year
  • TSLX 2014
  • BLTE 2022
  • Fundamental
  • Price
  • TSLX $23.49
  • BLTE $57.37
  • Analyst Decision
  • TSLX Strong Buy
  • BLTE Strong Buy
  • Analyst Count
  • TSLX 7
  • BLTE 4
  • Target Price
  • TSLX $22.79
  • BLTE $96.33
  • AVG Volume (30 Days)
  • TSLX 417.3K
  • BLTE 28.2K
  • Earning Date
  • TSLX 02-13-2025
  • BLTE 03-10-2025
  • Dividend Yield
  • TSLX 8.86%
  • BLTE N/A
  • EPS Growth
  • TSLX N/A
  • BLTE N/A
  • EPS
  • TSLX 2.03
  • BLTE N/A
  • Revenue
  • TSLX $482,526,000.00
  • BLTE N/A
  • Revenue This Year
  • TSLX N/A
  • BLTE N/A
  • Revenue Next Year
  • TSLX N/A
  • BLTE N/A
  • P/E Ratio
  • TSLX $11.58
  • BLTE N/A
  • Revenue Growth
  • TSLX 10.14
  • BLTE N/A
  • 52 Week Low
  • TSLX $19.50
  • BLTE $31.01
  • 52 Week High
  • TSLX $23.66
  • BLTE $86.53
  • Technical
  • Relative Strength Index (RSI)
  • TSLX 80.47
  • BLTE 48.86
  • Support Level
  • TSLX $21.93
  • BLTE $55.90
  • Resistance Level
  • TSLX $23.15
  • BLTE $58.54
  • Average True Range (ATR)
  • TSLX 0.34
  • BLTE 2.70
  • MACD
  • TSLX 0.09
  • BLTE 0.24
  • Stochastic Oscillator
  • TSLX 90.20
  • BLTE 52.14

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Share on Social Networks: